Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.

Teira R, Vidal F, Muñoz-Sánchez P, Geijo P, Viciana P, Ribera E, Domingo P, Castaño M, Martínez E, Roca B, Puig T, Estrada V, Deig E, Galindo MJ, de la Fuente B, Lozano F, Montero M, Muñoz-Sanz A, Sanchez T, Terrón A, Romero-Palacios A, Lacalle JR, Garrido M, Suárez-Lozano I; VACH Study Group.

HIV Med. 2016 Aug 1. doi: 10.1111/hiv.12413. [Epub ahead of print]

PMID:
27476742
2.

Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.

Pedrol E, Llibre JM, Tasias M, Currán A, Guardiola JM, Deig E, Guelar A, Martínez-Madrid O, Tikhomirova L, Ramírez R; RELAX Study Group.

HIV Med. 2015 Nov;16(10):628-34. doi: 10.1111/hiv.12298. Epub 2015 Aug 4.

PMID:
26238151
3.

[Barriers to ART initiation in HIV infected subjects and with treatment indication in Spain. Why don't they start their treatment? Bridgap Study].

Viciana-Fernández P, Falcó V, Castaño M, de los Santos-Gil I, Olalla-Sierra J, Hernando A, Deig E, Clotet B, Knobel H, Podzamczer D, Pedrol PD; Grupo de trabajo Bridgap.

Enferm Infecc Microbiol Clin. 2015 Jun-Jul;33(6):397-403. doi: 10.1016/j.eimc.2014.06.012. Epub 2015 Jan 7. Spanish.

PMID:
25577557
4.

ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study.

Podzamczer D, Rozas N, Domingo P, Ocampo A, Van den Eynde E, Deig E, Vergara A, Knobel H, Pasquau J, Antela A, Crespo M, Clotet B, Muñoz J, Fernandez P, Geijo P, de Castro ER, Diz J, Casado A, Torres C.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19814. doi: 10.7448/IAS.17.4.19814. eCollection 2014.

5.

[Reasons for antiretroviral treatment change in HIV+ patients in Spain in 2010-2011. SWITCH AUDIT Study].

Pedrol E, Viciana P, Arranz A, Pasquau J, Deig E, Tasias M; SWITH AUDIT study group.

Rev Esp Quimioter. 2014 Jun;27(2):93-7. Spanish.

6.

Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.

Estrada V, Geijo P, Fuentes-Ferrer M, Alcalde ML, Rodrigo M, Galindo MJ, Muñoz A, Domingo P, Ribera E, Cosín J, Viciana P, Lozano F, Terrón A, Vergara A, Teira R, Muñoz-Sánchez J, Roca B, Sánchez T, López-Aldeguer J, Deig E, Vidal F, Pedrol E, Castaño-Carracedo M, Puig T, Garrido M, Suárez-Lozano I.

BMC Womens Health. 2011 Aug 4;11:36. doi: 10.1186/1472-6874-11-36.

7.

[Efficacy and safety of the substitution of zidovudine by nevirapine in treatments based on three nucleoside analogue reverse transcriptase inhibitors in HIV-1 infected patients].

Tasias M, Ruiz S, Deig E, Pedrol E.

Enferm Infecc Microbiol Clin. 2011 Aug-Sep;29(7):556-7. doi: 10.1016/j.eimc.2011.03.004. Epub 2011 May 11. Spanish. No abstract available.

PMID:
21565428
8.

Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients.

Curran A, Gutirerrez M, Deig E, Mateo G, Lopez RM, Imaz A, Crespo M, Ocaña I, Domingo P, Ribera E.

J Antimicrob Chemother. 2010 Oct;65(10):2195-203. doi: 10.1093/jac/dkq295. Epub 2010 Aug 16.

9.

Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.

Moltó J, Deig E, Valle M, Maria Llibre J, Miranda C, Cedeño S, Valero S, Negredo E, Clotet B.

Ther Drug Monit. 2010 Feb;32(1):93-6. doi: 10.1097/FTD.0b013e3181cb479f.

PMID:
20040897
10.

Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study.

Falcó V, Olmo M, del Saz SV, Guelar A, Santos JR, Gutiérrez M, Colomer D, Deig E, Mateo G, Montero M, Pedrol E, Podzamczer D, Domingo P, Llibre JM.

J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):26-31. doi: 10.1097/QAI.0b013e31817bec64.

PMID:
18667930
11.
12.

[Efficacy and safety of a reduced-dose of stavudine in HIV-infected patients under immunological and virological stable conditions].

Pedrol E, Martín T, del Pozo MA, Flores J, Sanz J, Cartón JA, Jusdado JJ, Arazo P, Ribera E, Deig E; Grupo de Estudio de Evaluación del uso de Análogos de Nucleósidos.

Med Clin (Barc). 2007 Sep 22;129(10):361-5. Spanish.

PMID:
17915129
13.

HIV-1-infected long-term non-progressors have milder mitochondrial impairment and lower mitochondrially-driven apoptosis in peripheral blood mononuclear cells than typical progressors.

Peraire J, Miró O, Saumoy M, Domingo P, Pedrol E, Villarroya F, Martínez E, López-Dupla M, Garrabou G, Sambeat MA, Deig E, Villarroya J, Chacón MR, López S, Fontanet A, Holmstrom M, Giralt M, Gatell JM, Vidal F.

Curr HIV Res. 2007 Sep;5(5):467-73.

PMID:
17896966
14.

Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir.

Miró O, Garrabou G, López S, Deig E, Vidal I, Infante AB, Cardellach F, Casademont J, Pedrol E.

Antivir Ther. 2006;11(5):625-30.

PMID:
16964831
15.

[Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia].

Soler A, Deig E, Guil J, Rodríguez-Martín M, Guelar A, Pedrol E.

Med Clin (Barc). 2006 Jul 15;127(7):250-2. Spanish.

PMID:
16942727
16.

[Clinical and pharmacokinetic interactions between methadone and nelfinavir (Nemesia study)].

Marco A, Deig E, Cadafalch J, Fuster M, Valls I, Pedrol E.

Med Clin (Barc). 2006 Jun 10;127(2):47-50. Spanish.

PMID:
16801002
17.

Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 years.

Vidal F, Peraire J, Domingo P, Broch M, Cairó M, Pedrol E, Montero M, Viladés C, Gutiérrez C, Sambeat MA, Fontanet A, Dalmau D, Deig E, Knobel H, Sirvent JJ, Richart C, Veloso S, Saumoy M, López-Dupla M, Olona M, Cadafalch J, Fuster M, Ochoa A, Soler A, Guelar A, González J; Chemokines and Long-Term Nonprogressive HIV01 Infection Study Group.

J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):17-22.

PMID:
16340468
18.

Spanish HIV-1-infected long-term nonprogressors of more than 15 years have an increased frequency of the CX3CR1 249I variant allele.

Vidal F, Viladés C, Domingo P, Broch M, Pedrol E, Dalmau D, Knobel H, Peraire J, Gutiérrez C, Sambeat MA, Fontanet A, Deig E, Cairó M, Montero M, Richart C, Mallal S; Chemokines LTNP Study Group.

J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):527-31.

PMID:
16284527
19.

Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.

Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.

Antivir Ther. 2005;10(5):605-14.

PMID:
16152754
20.

[Treatment of symptomatic hyperlactatemia and lactic acidosis in HIV+ patients under nucleoside reverse transcriptase inhibitors].

Pedrol E, Ribell M, Deig E, Villà Mdel C, Miró O, Garrabou G, Soler A.

Med Clin (Barc). 2005 Jul 9;125(6):201-4. Spanish.

PMID:
16022831
Items per page

Supplemental Content

Write to the Help Desk